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Abstract
Background: With its high morbidity and mortality, acute myocardial infarction (AMI) places a major burden on
society and on individual patients. Correct, early correct diagnosis is crucial to the management of AMI.
Methods: In this study, the expression of circulating miR-486 and miR-150 was investigated in AMI patients and the
two miRNAs were evaluated as potential biomarkers for AMI. Plasma samples from 110 patients with AMI (65 patients
with ST-segment elevation myocardial infarction (STEMI) and 45 patients with non-ST-segment elevation myocardial
infarction (NSTEMI)) and 110 healthy adults were collected. Circulating levels of miR-486 and miR-150 were detected
using quantitative real-time PCR in plasma samples.
Results: Results showed that the levels of miR-486 and miR-150 were significantly higher in AMI patients than in
healthy controls. Receiver operating characteristic (ROC) curve analyses indicated that the two plasma miRNAs were of
significant diagnostic value for AMI, especially NSTEMI. The combined ROC analysis revealed an AUC value of 0.771 in
discriminating AMI patients from healthy controls and an AUC value of 0.845 in discriminating NSTEMI patients from
healthy controls.
Conclusion: Results indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be
novel and powerful biomarkers for AMI, especially for NSTEMI.
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Background
Acute myocardial infarction (AMI) is the acute necrosis of
myocardial tissue due to persistent and severe ischemia
[1]. AMI is one of the most frequently occurring cardio-
vascular diseases and one of the leading causes of morbid-
ity and mortality in both developed and developing
countries [2–4]. With China’s aging population and the
projected increase in the rate of this disease, it is estimated
that 16 million people will suffer from AMI in 2020 and
23 million in 2030 [5]. Because it is the world’s largest de-
veloping country, China is challenged to provide care for
its large and growing population of AMI patients [6]. AMI
is separated into two categories based on changes seen in
the electrocardiography (ECG): ST-segment elevation
myocardial infarction (STEMI) and non-ST-segment ele-
vation myocardial infarction (NSTEMI). In STEMI, the
infarct-related artery is usually totally occluded by fibrin-
rich clots, and immediate reperfusion therapy is the initial
approach. In contrast, the initial conservative strategy or
the initial invasive strategy can be taken in patients with
NSTEMI whose infarct-related artery is partially occluded
by platelet-rich clots. Prompt diagnosis is critical to con-
trolling the development of AMI and initiating appropri-
ate therapy to reduce the mortality rate and improve
prognosis. ECG is significant to differentiate the two AMI
types. However, ECG has several limitations. For example,
normal findings do not exclude the possibility of AMI.
NSTEMI patients are often misdiagnosed because they
frequently lack typical symptoms and obvious elevated
ST-segment in their ECG. At present, some conventional
biomarkers, such as blood troponins, cardiac myoglobin
and creatine kinase-MB (CK-MB) are wildly used for
clinical diagnosis [7]. However, the search for novel bio-
markers for AMI is ongoing.
In recent years, with advances in molecular biology and
technology, nucleotide-based biomarkers that may en-
hance diagnostic or prognostic effectiveness have attracted
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considerable attention. MicroRNAs (miRNAs) are small,
non-coding, cellular RNAs 17–27 nucleotides in length. By
pairing with the 3’ UTR of target mRNAs, they act as
sequence-specific regulators of gene expression through
translational repression and transcript cleavage [8, 9]. Many
studies suggest that miRNAs play crucial roles in a variety
of essential biological processes, including proliferation,
development, differentiation, and apoptosis [10]. Aberrant
expression of miRNAs in tissues contributes to various
diseases, such as cancer and cardiovascular disease [11–13].
In addition, many miRNAs are remarkably stable and read-
ily detectable in the peripheral blood or plasma [14, 15].
The levels of circulating miRNAs are different in specific
ways under specific pathological conditions [16–18]. This
indicates that circulating miRNAs may be excellent candi-
date diagnostic and prognostic biomarkers of various dis-
eases [19, 20]. Recently, it has been reported that the levels
of several miRNAs such as miR-1, miR-133a, miR-208b,
miR-499, and miR-328 in the blood and plasma alter during
AMI, suggesting the diagnostic value of circulating miR-
NAs in early AMI [21–26].
It has been reported that miR-486 is a potent modula-
tor in cardiac/skeletal muscle and miR-150 is involved in
many cardiovascular diseases [27]. We also performed a
preliminary plasma miRNA microassay chip analysis of
AMI patients and healthy controls and the results
showed significant changes in the levels of miR-486 and
miR-150 in AMI patients which was in accordance with
a recent study about serum miR-486 and miR-150 [28].
The purpose of the present study was to measure the
levels of circulating miR-486 and miR-150 in AMI pa-
tients, so as to determine whether miR-486 and miR-150




This study was approved by the Research Ethics Com-
mittee of Zhengzhou University, China, and the samples
were collected with each patient’s informed consent.
One hundred and ten consecutive AMI patients were
enrolled in this study from the First Affiliated Hospital of
Zhengzhou University between June 2013 and May 2014.
The clinical characteristics of all patients are given in
Table 1. AMI patients were diagnosed using the following
criteria: 1) acute ischemic chest pain; 2) abnormal electro-
cardiogram (pathological Q wave, ST-segment elevation, or
depression); 3) levels of myocardial necrosis markers (tro-
ponins (cTns) and creatine kinase (CK)) more than twice
the upper limit of the normal range. These patients were
admitted to hospital no more than 24 h after the emer-
gence of symptoms. Patients with previous MI or percu-
taneous coronary intervention (PCI), any hematological
disease, acute or chronic infection, significant hepatic
dysfunction, kidney failure (glomerular filtration rate
(GFR) < 15 mL/min/1.73 m2 or on dialysis), or known or
treated malignancies were excluded. In addition, 110
healthy adult volunteers (normal electrocardiograms
and no history of cardiovascular diseases) were enrolled
in this study. Five milliliter venous blood samples of pa-
tients with AMI were collected in EDTA anticoagulant
tubes at admission. Samples were centrifuged at 3000 ×
g for 10 min at 4 °C, then the supernatant was isolated
and centrifuged at 12,000 × g for 10 min at 4 °C. Plasma
was collected and stored at −80 °C until RNA extraction.
RNA extraction
Total RNA was extracted from plasma using an miRNeasy
Serum/Plasm Kit (Qiagen), in accordance with the manu-
facturer’s instructions. The RNA was dissolved in 20 μl of
diethylpyrocarbonate-treated (DEPC-treated) water. The
concentration and quality of the RNA samples were
determined using NanoDrop2000c spectrophotometer
(NanoDrop, Thermo Fisher Scientific, U.S.).
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
The levels of expression of miR-486 or miR-150 were
quantified using quantitative real-time PCR (qRT-PCR)
using TaqMan human microRNA assay kits (Applied
Biosystems) according to the manufacturer’s instruc-
tions. The 15 μL RT reaction mix contains 0.3 μL of
100 mM dNTPs, 3 μL of MultiScribe Reverse Tran-
scriptase (50 U/μL), 1.5 μL of 10 × RT buffer, 0.19 μL of
RNase inhibitor (20 U/μL), 6 μL of RT primer, 3 μL of
RNA sample and 1.01 μL of Nuclease-free water. For
RNA from plasma samples, the concentration was di-
luted to 180 ng/μL. The reagent mixes were incubated at
16 °C for 30 min, 42 °C for 30 min and 85 °C for 5 min,
the RT products were stored at – 20 °C until used for
qRT-PCR. The 20 μL PCR reaction mix includes 1.0 μL
20 × TaqMan MicroRNA Assays, 0.16 μL RT product,
10 μL TaqMan Universal Master Mix II, No AmpErase
UNG (2×), 8.84 μL Nuclease-free water. The PCR cycles
consisted of an initial denaturation at 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for
60 s. U6 snRNA served as an internal normalized refer-
ence. Each specimen was measured in triplicate. The
relative expression values of each miRNA were calcu-
lated using the 2-△Ct method.
Biochemical assays
The concentrations of plasma cardiac troponin T (cTnT)
were measured using a Roche high-sensitivity assay per-
formed on a Cobas C8000 system (Roche Diagnostics,
Germany) with a detection limit of 0.003 μg/L, a 99th-
percentile cutoff of 0.014 μg/L, and a CV of ≤10 % at
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0.013 μg/L. CK-MB was also measured on Cobas C8000
instrument with a Roche IFCC-recommended method.
Statistical analysis
Statistical treatment was performed using SPSS 20.0
software. All data were subjected to a normality test
(Kolmogorov-Smirnov). Continuous data are presented
as mean ± SD or median with interquartile range. Cat-
egorical variables are presented as counts and percent-
ages. Independent sample t-tests and Mann–Whitney U
tests were used to compare two groups of continuous
variables and the chi-square test was used for categor-
ical variables. Receiver operating characteristic (ROC)
curve analysis and comparison of the derived area under
the curve (AUC) were performed to assess miRNAs as
predictors for distinguishing AMI from healthy con-
trols. Multiple logistic regression analysis was carried
out for evaluating the combined diagnostic accuracy of
circulating miRNAs. The statistical significance was set
at P < 0.05.
Results
Clinical characteristics of patients
Among 110 patients with AMI, 65 were diagnosed with
STEMI and 45 were diagnosed with NSTEMI. Both the
AMI group and control group were predominantly male
(87/110 in the AMI group and 83/110 in the control
group). The basic clinical characteristics of the patients
in this study are shown in Table 1. There were no obvi-
ous differences in disease or personal history including
hypertension, hyperlipidemia, diabetes, or smoking be-
tween AMI patients and control cases. Significant differ-
ences were observed between the two groups in white
blood cells (WBC), CK-MB, cTnT, and the left ventricu-
lar ejection fraction (EF).
Circulating miR-486 or miR-150 levels were significantly
higher in AMI patients
The blood samples of AMI patients were immediately
collected after admission. We detected the miR-486 and
miR-150 levels in plasma of 110 AMI patients (65
Table 1 Clinical features, risk factors, and laboratory data of the cohort
Characteristics All cohort
(n = 220)
AMI cases (n = 110) Control cases
(n = 110)
P
STEMI (n = 65) NSTEMI (n = 45)
Age (years) 57.99 ± 11.63 57.54 ± 12.07 57.93 ± 11.98 58.28 ± 11.32 0.712
Men/women (n/n) 170/50 51/14 36/9 83/27 0.520
Risk factors
Hypertension (Y/N) 103/117 34/31 17/28 52/58 0.893
Hyperlipidemia (Y/N) 26/119 9/56 3/42 14/96 0.676
Diabetes mellitus (Y/N) 50/170 13/52 10/35 27/83 0.520
Smoking (Y/N) 47/173 15/50 8/37 24/86 0.869
Physical examination
SBP (mmHg) 124.64 ± 18.89 125.88 ± 21.51 121.76 ± 16.35 124.23 ± 20.26 0.754
DBP (mmHg) 75.95 ± 11.58 76.68 ± 13.70 73.31 ± 9.60 77.30 ± 10.68 0.132
Heart rate (beats/ min) 74.10 ± 12.98 74.20 ± 13.03 75.38 ± 11.54 73.53 ± 13.57 0.511
Lab examination
TC (mmol/L) 3.9232 ± 0.99 3.91 ± 1.07 3.92 ± 1.09 3.90 ± 0.91 0.998
TG (mmol/L) 1.3727 ± 0.80 1.48 ± 1.17 1.39 ± 0.88 1.30 ± 0.42 0.197
HDL (mmol/L) 1.0470 ± 0.22 0.98 ± 0.23 1.05 ± 0.27 1.09 ± 0.18 0.080
LDL (mmol/L) 2.5300 ± 1.00 2.52 ± 0.97 2.43 ± 0.87 2.58 ± 1.08 0.504
WBC (×109/L) 8.589 ± 3.62 9.51 ± 4.13 10.02 ± 4.01 7.46 ± 2.68 <0.001
BUN (mmol/L) 5.9365 ± 2.73 6.25 ± 3.05 6.16 ± 2.64 5.66 ± 2.55 0.135
CK-MB (U/L) 35.68 ± 59.13 58.80 ± 90.75 48.46 ± 58.17 16.79 ± 8.63 <0.001
Cardiac troponin T (ng/mL) 0.68 ± 1.40 1.44 ± 1.89 1.16 ± 1.57 0.05 ± 0.12 <0.001
EF% 58.14 ± 7.83 56.35 ± 7.89 55.80 ± 8.28 60.15 ± 7.13 <0.001
Abbreviations: AMI acute myocardial infarction, STEMI ST-segment-elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, SBP
systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG total triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein, WBC
white blood cell, BUN blood urea nitrogen, CK-MB creatine kinase-MB, EF ejection fractions
Data are expressed as mean ± standard deviation. P: comparison between AMI patients with healthy controls
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STEMI patients and 45 NSTEMI patients) and 110 non-
AMI controls to assess the value of circulating miRNAs
levels for predicting the onset of AMI. As shown in Fig. 1a,
the plasma concentrations of miR-486 were markedly higher
in AMI patients than in healthy controls (P < 0.001). In
addition, the expression of miR-150 was markedly higher
during the early phase, shortly after the occurrence of AMI
in patients, than in controls (P < 0.001) (Fig. 1b).
Circulating miR-486 and miR-150 expression levels as
predictors of AMI
To further evaluate the predictive power of circulating miR-
486 and miR-150 for AMI, ROC curve and areas under
ROC curve (AUC) analyses were performed. As shown in
Fig. 2a and b, ROC curve analysis of miR-486 or miR-150
exhibited strong differentiation power between AMI pa-
tients and healthy controls during the early phase of AMI.
The AUC of miR-486 or miR-150 in AMI patients was
0.731 (P < 0.001), 0.678 (P < 0.001). Interestingly, the com-
bination of the two miRNAs resulted in a higher AUC
value of 0.771 (P < 0.001) than the AUC of miR-486 or
miR-150 (Fig. 2a, b, c). These data suggested that the com-
bination of circulating miR-486 and miR-150, which both
had both high sensitivity and specificity, might be more
suitable than miR-486 or miR-150 alone for diagnosing
AMI.
Expression pattern of miR-486 and miR-150 in STEMI and
NSTEMI
A follow-up investigation was performed to determine
whether the plasma miRNA levels in patients were asso-
ciated with specific types of AMI. There was distinct dif-
ference between the level of plasma miR-486 (P = 0.015)
and miR-150 (P = 0.016) between STEMI patients and
NSTEMI patients (Fig. 3a and b). ROC curve analysis of
miRNAs showed the AUC of plasma miR-486 and miR-
150 in STEMI patients to be 0.695 and 0.639, respect-
ively (Fig. 4a and b), which was lower than in NSTEMI
patients (0.782, 0.734) (Fig. 4d and e). There was also a
higher AUC value, 0.845, for the combination of miR-
486 and miR-150 in the NSTEMI group than in the
STEMI group (Fig. 4c and f). These data suggested miR-
486 or miR-150 were highly sensitive and specific for the
discrimination of NSTEMI cases from controls, and the
combination of the two miRNAs was shown to predict
NSTEMI with even higher power.
Fig. 1 Expression of circulating miRNAs in AMI patients and control group. Plasma samples were collected upon admission no more than 24 h
after AMI onset. a: The relative expression levels of miR-486 between AMI group and control group (P < 0.001). b: The relative expression levels of
miR-150 between AMI group and control group (P < 0.001). Results were reported as mean ± SD
Fig. 2 Receive operating characteristic (ROC) curves analyzed for the diagnostic value of circulating miRNAs. ROC curve for plasma (a) miR-486,
(b) miR-150, and (c) the combination of the two miRNAs were able to distinguish AMI from the control group
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Discussion
AMI remains an important cause of death in the world.
Early and reliable diagnosis may prompt patients to
undergo reperfusion therapy early and this may improve
the survival rate of AMI patients.
Recent studies have revealed that miRNA are important
regulators in the pathogenesis of many diseases. Results
have demonstrated that miRNAs can be exported or re-
leased by cells and circulate in bloodstream; these are called
circulating miRNAs [29]. Numerous circulating miRNAs
are involved in AMI. These include cardiac-specific miR-
NAs (miR-208a) and non-cardiac-specific miRNAs (miR-
126, miR-328, miR-134) [30–33]. On account of their tissue
specificity, rapid release kinetics and stability in plasma, cir-
culating miRNAs are considered promising biomarkers for
detecting a large number of diseases, especially cardiovas-
cular diseases. However, studies on the expression of circu-
lating miRNAs in AMI patients are limited.
In this study, qRT-PCR results showed that plasma
miR-486 and miR-150 were visibly overexpressed in 110
AMI patients. The ROC analyses showed that the two
miRNAs might be suitable diagnostic markers of AMI.
Here, the expression of miRNAs was measured in STEMI
patients and NSTEMI patients. There was a distinct differ-
ence in levels of miR-486 and miR-150 expression be-
tween the STEMI and NSTEMI groups. The results of
Fig. 3 Relative expression of miRNAs in patients with STEMI and NSTEMI. The plasma levels of (a) miR-486 and (b) miR-150 were higher in the
NSTEMI group than in the STEMI group. Results are reported as mean ± SD
Fig. 4 Evaluation of plasma microRNAs for the diagnosis of STEMI and NSTEMI by ROC curve analysis. The AUCs of plasma (a) miR-486, (b) miR-150,
and (c) the combination of the two miRNAs were 0.695, 0.639, and 0.719 in the STEMI group. The AUCs of plasma (d) miR-486, (e) miR-150, and (f) the
combination of the two miRNAs were higher (0.782, 0.734, and 0.845, respectively) in the NSTEMI group
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ROC analyses indicated that miR-486 and miR-150 are
specific and sensitive for the early diagnosis of NSTEMI.
miR-486 is a muscle-enriched miRNA. It was found to
be downregulated in several muscular diseases, such as
Duchenne’s muscular dystrophy and denervation-induced
muscle atrophy [34, 35]. Overexpression of miR-486 could
lead to muscle hypertrophy. The upregulation of circulat-
ing miR-486 in AMI patients may be related to cardiac
hypertrophy. miR-150, an miRNA related to inflamma-
tion, was reported to be implicated in the pathogenesis of
various cardiovascular diseases [36–38]. A microarray
screen of plasma samples showed reduced levels of miR-
150 in patients with pulmonary arterial hypertension com-
pared to healthy controls. Moreover, plasma miR-150 level
in these patients was a significant predictor of survival
[39]. miR-150 was also dysregulated in serum of patients
with unstable angina pectoris. The diagnostic accuracy for
unstable angina pectoris was obviously improved by ap-
plying the miRNA panel including miR-132, miR-150, and
miR-186 [40]. Furthermore, miR-150 may inhibit cardiac
structural and functional remodeling during ischemic
injury partly by direct repression of the pro-apoptotic gene
egr2 and p2x7r (pro-inflammatory ATP receptor) in cardi-
omyocytes [41]. In addition, the transcription factor c-
Myb, NOTCH3 receptor, and nonmetastatic melanoma
protein B were the potential targets of miR-150. Dysregu-
lation of these two miRNAs may be associated with patho-
logical conditions other than cardiac damage.
Conclusion
In conclusion, results demonstrated that miR-486 and miR-
150 levels to be significantly high in the plasma of AMI pa-
tients, both STEMI and NSTEMI, suggesting that circulat-
ing miR-486 and miR-150 might be responsible for the
onset of AMI, especially NSTEMI. It is possible that miR-
486 and miR-150 could be suitable biomarkers against AMI.
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